Melanotan II (MT-II) is a synthetic, cyclic analogue of α-melanocyte-stimulating hormone (α-MSH) that researchers use as a stable probe of melanocortin-receptor biology. This article reviews what the compound is, how it engages the pigmentation pathway in experimental models, and how honest the underlying evidence actually is.

What Melanotan II is

Melanotan II is a small, chemically modified peptide built on the active core of α-melanocyte-stimulating hormone. In the pilot phase-I report that introduced it clinically, the molecule was described as a cyclic heptapeptide with the sequence Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰-NH₂, closed by a lactam bridge, and it showed “superpotent melanotropic activity in vitro”¹. Two engineering choices distinguish it from the natural hormone: the ring structure constrains the peptide into a bioactive conformation, and non-natural residues (such as norleucine and D-phenylalanine) slow the enzymatic degradation that gives native α-MSH a very short half-life².

These properties are the reason MT-II became a laboratory workhorse rather than a curiosity. A longer-lasting, more potent agonist is easier to study across the hours-long timescales of melanogenesis assays and across the melanocortin receptor family. Historically, MT-II and its linear cousin melanotan I were patented and taken into early human testing precisely because they behaved as durable melanocortin agonists². Qovigen supplies MT-II strictly as a reference reagent for that kind of receptor and pigmentation work; the Melanotan II – 10 mg presentation is intended for in vitro and preclinical use only.

Mechanism of action at MC1R

The melanocortin-1 receptor (MC1R) is a G_s-coupled receptor expressed preferentially on melanocytes, and it is the primary switch that MT-II is used to interrogate. When an agonist such as α-MSH or MT-II binds MC1R, the receptor raises intracellular cyclic AMP (cAMP) and activates protein kinase A (PKA). PKA-driven signalling then converges on microphthalmia-associated transcription factor (MITF), the master regulator of the melanocyte, which in turn upregulates the enzymatic machinery of pigment synthesis — tyrosinase and the tyrosinase-related proteins³.

Reviews of MC1R signalling stress that this is not a single linear wire. Beyond the canonical cAMP–MITF axis, the receptor also recruits mitogen-activated protein kinases and AKT, and its output is shaped by intracellular partners including β-arrestins, the phosphatase PTEN and the E3 ubiquitin ligase MGRN1³. The MC1R gene is also highly polymorphic, and loss-of-function variants shift signalling toward weaker pigmentation and higher photodamage sensitivity — a genetic backdrop that makes a potent, well-characterised agonist useful for probing what fully functional receptors do³.

The physiological version of this circuit is the delayed tanning response. Ultraviolet-B exposure damages keratinocyte DNA, stabilising p53, which drives transcription of pro-opiomelanocortin (POMC); POMC is processed to release α-MSH, which then stimulates melanocyte MC1R and, through MITF, increases melanogenesis⁴. MT-II is, in essence, a pharmacological way to engage the downstream half of that pathway directly in an experimental system, without the upstream UV insult.

Eumelanin, photoprotection and DNA repair

Melanocytes make two broad pigment classes: brown-black eumelanin and red-yellow pheomelanin. MC1R activation biases synthesis toward eumelanin, the pigment generally associated with ultraviolet absorption in the epidermis⁶. In experimental terms, an MC1R agonist therefore does more than darken a culture — it shifts the qualitative output of the melanocyte toward the pigment type most studied for its light-absorbing behaviour.

A more surprising strand of research is that melanocortin signalling appears to influence genome-maintenance pathways independently of pigment. In cultured human melanocytes, α-MSH acting through MC1R and PKA promotes phosphorylation of the kinase ATR at serine 435, a modification that facilitates recruitment of the XPA protein to sites of UV damage and enhances nucleotide excision repair (NER)⁵. Separately, α-MSH has been reported to reduce oxidative stress in melanocytes through a p53-dependent mechanism, raising base-excision-repair enzymes such as OGG1 and APE-1/Ref-1⁶. Purpose-built α-MSH analogues have reproduced these effects, reducing UV-induced DNA photoproducts in a manner that depended on a functional receptor⁷.

Two honest caveats belong with these findings. First, the DNA-repair work was performed largely with α-MSH and short designed analogues in cell culture, not with MT-II in intact human skin, so extrapolation is a hypothesis rather than a demonstrated equivalence. Second, these are mechanistic observations in models; they do not establish any protective outcome in a living organism.

Beyond pigment: other melanocortin receptors

MT-II is not selective for MC1R. It engages other members of the melanocortin receptor family, and much of the compound’s research interest — and its complications — comes from that promiscuity. The central melanocortin system, built around MC3R and MC4R in the hypothalamus and brainstem, is a well-established regulator of energy balance, and pharmacological agonism of MC4R suppresses food intake in rodent models⁸. MT-II is frequently used as the tool agonist in these circuits; for example, microinjection of MT-II into brainstem nuclei reduced food intake and body weight in mice⁹.

The same non-selectivity extends to sexual-behaviour research. The early human study of MT-II noted spontaneous penile erections as a consistent, dose-related observation alongside tanning¹, and this steered development toward a related cyclic heptapeptide, bremelanotide (PT-141), which has since been characterised pharmacologically as a melanocortin-receptor agonist¹². That translational thread — from a broad melanocortin agonist to a more targeted derivative — is documented in the historical review of the field², and the PT-141 – 10 mg reference material is studied in that receptor context. The broader message from melanocortin drug development is that receptor selectivity, not raw potency, is what separates a research probe from a usable therapeutic⁸.

Melanocortin receptors relevant to MT-II research

What the experimental record shows

The evidence base for MT-II is uneven, and it is worth separating its layers.

Cell-culture studies

Most mechanistic detail comes from melanocyte and melanoma cell models, where melanocortin agonists reliably raise cAMP, tyrosinase activity and melanin content, and where the DNA-repair and antioxidant effects described above were characterised⁵⁶. Because MT-II is more potent and more stable than α-MSH, it is convenient as a positive-control agonist in these assays¹.

Animal studies

Rodent work has explored both ends of the receptor family: pigmentary responses via MC1R and central metabolic responses via MC4R, with MT-II microinjection producing measurable suppression of food intake and body weight⁹. These models establish that the compound is centrally active, not merely dermatologically active.

Human data

Human evidence is thin and old. The pilot phase-I study dosed three male volunteers and reported increased facial and upper-body pigmentation by quantitative reflectance, along with nausea, a yawning-and-stretching complex, somnolence at higher doses, and dose-related erections¹. That is a hypothesis-generating observation in a handful of subjects, not a controlled efficacy or safety demonstration. No large modern human trials of MT-II itself underpin the tanning claims that circulate in consumer settings.

How researchers use MT-II

Given the above, MT-II is best understood as a broadly acting melanocortin agonist that is valuable precisely because it is potent and stable. In pigmentation biology it is used to drive and quantify melanin synthesis, tyrosinase activity and MITF-dependent gene expression in melanocyte cultures. In photobiology it serves as a way to probe how MC1R engagement intersects with UV-response and DNA-repair pathways⁵⁷. In neuroendocrine and metabolic research it is a standard MC3R/MC4R agonist for interrogating appetite and energy-balance circuits⁸⁹.

Reconstitution for these assays is typically performed with bacteriostatic water; laboratories pairing MT-II with a diluent often stock BAC Water – 10 ml for that purpose. As with any reference peptide, reproducibility depends on consistent identity and purity between lots, which is why batch-level analytical documentation matters for melanocortin work.

Safety signals and regulatory status

The dermatology literature is unusually clear about why MT-II is not a benign cosmetic. A review of unregulated α-MSH analogue use catalogued melanocytic changes in existing moles and the emergence of new, sometimes dysplastic, nevi, and noted case reports describing melanomas arising in moles during or shortly after melanotan use; the authors were careful to state that a causal link is not established, while stressing the pattern as a safety concern¹⁰. Vascular and urological harms are also documented, including a case of low-flow priapism requiring emergency intervention after subcutaneous melanotan injection¹¹.

These reports reflect two problems that compound each other: the intrinsic pharmacology of a non-selective, long-acting melanocortin agonist, and the fact that material sold outside regulated channels has uncertain identity, purity and dose. National health agencies have issued warnings against human use of melanotan I and II, and MT-II holds no marketing approval in major jurisdictions¹⁰. For a research setting the practical conclusion is straightforward: MT-II is a reagent to be studied in controlled models, not administered to people.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.